Alzheimer’s-Immune System Connection Revealed
An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimer’s disease.
An international research team reports that they have identified a second gene variant that confers a high risk of acquiring the more common, late-onset form of Alzheimer’s disease. The gene was also found to predict poorer cognitive function in older individuals who do not have Alzheimer’s disease, according to the investigators.
The study, carried out by deCODE Genetics and Illumina, along with scientists from the National Hospital of Iceland and collaborators from Holland, Germany, and the U.S., was reported today in the New England Journal of Medicine.
“The discovery of variant TREM2 is important because it confers high risk for Alzheimer’s and because the gene’s normal biological function has been shown to reduce [the] immune response that may contribute to the disease,” explained lead author Kari Stefánsson, M.D., Dr. Med., CEO of deCODE Genetics. “These combined factors make TREM2 an attractive target for drug development.”
While a number of common, low-risk variants have been reported to associate with late-onset Alzheimer’s, the ε4 allele of Apolipoprotein E, originally discovered as a risk factor for the disease in 1993, has been the most important sequence variant because of its prevalence in the population and the size of its effect on risk.
TREM2, while rarer in the general population than the ApoE ε4 allele, confers a comparable risk of the disease and plays a significant role in the central nervous system. In preclinical studies, TREM2 has been found to regulate the clearing of cell debris and amyloid protein, a component of the amyloid plaques associated with Alzheimer's disease. TREM2 has also been shown to exercise a regulatory control of inflammation, which has been associated with Alzheimer’s and cognitive decline.
“Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimer’s disease,” said Dr. Stefánsson. “Reduced TREM2 activity may lead to brain damage through increased inflammatory response.”
After carrying out a large number of genome sequencing and genotyping operations, deCODE researchers identified approximately 41 million markers, including 191,777 functional variants, from 2,261 Icelandic samples. These variants were then analyzed against the genomes of 3,550 persons with Alzheimer’s disease and a control population over the age of 85 without a diagnosis of the disease. The association analysis used to identify the variant TREM2 in the Icelandic population was then replicated against other control populations with Alzheimer’s disease maintained in the U.S., Germany, the Netherlands, and Norway.
“Using this approach, we have recently reported variants that greatly influence the risk of developing other diseases, including ovarian cancer, gliomas, gout, and sick sinus syndrome,” continued Dr. Stefánsson. “So-called big data research has evolved to a new level of sophistication due to new research tools, access to expanded and high-quality genomic data sets, and certainly the profound analytic skill level of investigators now combining sequence data and biological knowledge to find drug targets.”
The issue of which genes are involved in early-onset and late-onset Alzheimer’s is not a clearcut division. Last February, scientists the Washington University School of Medicine in St. Louis reported in PloS One that rare variants of three genes associated with the early onset of the disease—APP, PSEN1, PSEN2—have also been discovered in patients with the late-onset form.
“The presence of variants in these genes…demonstrates that factors other than the mutation can impact the age at onset,” wrote the scientists. They believe this finding could eventually lead to changes in how the disease is classified.
Related News
-
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News A Day in the Life of a Start-Up Founder and CEO
At CPHI we work to support Start-Up companies in the pharmaceutical industry and recognise the expertise and innovative angles they bring to the field. Through our Start-Up Programme we have gotten to know some of these leaders, and in this Day in the ... -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance